SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending after a short-seller released a report alleging substantial financial overstatements and undisclosed related-party transactions, raising serious questions about the company's accounting practices. This has sparked intense community debate over its fundamental health, market manipulation, and the credibility of analyst ratings, with many drawing parallels to past major fraud accusations.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is surging to unprecedented new highs, fueled by broad market concerns over dollar debasement, inflation, and geopolitical instability, leading many to declare it the ultimate "safe play" and the "death of fiat." However, this rapid, "parabolic" ascent is also sparking intense debate, with some community members calling it "bubble territory" and aggressively shorting the perceived mania.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending due to recent analyst downgrades, intensifying an already negative market sentiment ahead of its crucial earnings report. The community is sharply divided, with bears citing a value trap and stiff competition, while bulls point to deep undervaluation, aggressive share buybacks, and new AI/partnership initiatives as catalysts for an imminent rebound. Investors are keenly watching for signs of fundamental strength to counter ongoing market skepticism.

Namib Minerals is a gold producer, developer and explorer with operations focused in Zimbabwe. The company was founded on June 5, 2025 and is headquartered in George Town, Cayman Islands.

Namib Minerals.

Namib Minerals

Namib Minerals (NAMM) is trending amidst soaring gold prices reaching all-time highs, igniting strong community interest. Discussions frequently revolve around a potential short squeeze, with many anticipating substantial price appreciation and actively watching for key resistance levels to break, driven by the stock's low float and high cost-to-borrow for shorts.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is generating significant buzz ahead of its anticipated earnings report, with investors sharply divided on whether the company's aggressive AI infrastructure spending will drive strong returns or disappoint. The community is actively debating the impact of these substantial investments and the potential for a volatile market reaction. This report is keenly watched as a key indicator for the broader tech sector, especially concerning AI development and capital expenditures.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is heavily trending as investors anticipate its upcoming earnings report, with community sentiment sharply divided and many expressing extreme frustration over the stock's recent price action. Despite a history of strong financial performance and expectations for another beat, shareholders are vocal about perceived market manipulation and the impact of a recent stock offering, while long-term holders view current levels as a significant buying opportunity ahead of potential S&P 500 inclusion and future growth.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending amidst high anticipation for upcoming clinical data presentations at a Glioblastoma scientific summit and recent Saudi FDA approval for a lung cancer therapy. The community is actively discussing the stock's significant short interest, anticipating potential short squeeze dynamics, and expressing strong conviction in the company's innovative 'BioShield' platform to deliver groundbreaking cancer treatments.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending after announcing a $75 million registered direct offering to a single institutional investor, intended to fund preparations for its upcoming Phase 3 MASH trial, which triggered significant pre-market volatility. The community is sharply divided, with some viewing the financing as a strategic de-risking move that bolsters confidence in the company's best-in-class pemvidutide, while others express frustration over dilution and a perceived lack of immediate partnership. Despite initial share price reactions, optimists highlight the institutional backing and a recent analyst $20 price target as validation for Altimmune's potential in the high-value MASH market.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as the market grapples with the Federal Reserve's decision to hold interest rates, with many community members labeling the outcome and Jerome Powell's press conference a "nothing burger" due to limited immediate price movement. This has led to frustration among options traders, as participants now keenly await upcoming big tech earnings for the next significant market catalyst amidst mixed signals on economic strength and inflation.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending after announcing a U.S. Air Force contract to advance multi-domain swarming capabilities using its SwarmOS AI platform, extending its technology to integrate satellite operations. The community is actively debating the significance of this development, with many optimistic about its implications for defense AI and robotics, while others express caution due to the undisclosed contract value and historical market reactions to similar news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2030 Earnings Forecast for MIRM Issued By HC Wainwright

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities researchers at HC Wainwright issued their FY2030 earnings per share estimates for Mirum Pharmaceuticals in a research note issued to...

Is Mirum Pharmaceuticals About to Soar in 2026?

Key PointsMirum Pharmaceuticals is at an inflection point...

Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High After Analyst Upgrade

Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High on Analyst Upgrade...

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, HC Wainwright Analyst Says

HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a "buy" rating in a research report on Monday...

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leading rare disease company, today announced the successful completion of its acquisition of Bluejay Therapeutics, a privately held biotechnology...

Expert Outlook: Mirum Pharmaceuticals Through The Eyes Of 11 Analysts

Joanne Quan Sells 6,911 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) insider Joanne Quan sold 6,911 shares of the firm's stock in a transaction on Tuesday, January 20th. The shares were sold at an average...

Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Emerald Advisers LLC

Emerald Advisers LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 20.9% during the 3rd quarter, according to its most recent filing with the Securities...

Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week High - Here's Why

Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High - Here's What Happened...

Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 6,911 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) insider Joanne Quan sold 6,911 shares of the firm's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.01	--	--	N/A
Q3 '25	-$0.14	$0.05	135.67%	BEAT
Q2 '25	-$0.33	-$0.12	63.22%	BEAT
Q1 '25	-$0.33	-$0.30	9.05%	BEAT
Q4 '24	-$0.26	-$0.49	-89.59%	MISSED

MIRM
Mirum Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest MIRM News

MIRMMirum Pharmaceuticals Inc